1. Immunology/Inflammation
  2. CD38

CD38

CD38 is a glycoprotein found on the surface of many immune cells, including T cells, B cells and natural killer cells. Additionally, CD38 has been shown to be a bifunctional enzyme expressing both ADP-ribosyl cyclase and cADPR hydrolase activities. The role of CD38 in immune cells ranges from modulating cell differentiation to effector functions during inflammation, where CD38 may regulate cell recruitment, cytokine release, and NAD availability. In line with a role in inflammation, CD38 appears to also play a critical role in inflammatory processes during autoimmunity. Because of CD38 expression is highly upregulated on human plasma cells and especially on multiple myeloma cells.Targeting of CD38 is one of the most important and promising treatment avenues to help patients suffering from multiple myeloma.

CD38 Related Products (18):

Cat. No. Product Name Effect Purity
  • HY-P99730
    Mezagitamab Inhibitor
    Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP)[1][2][3].
  • HY-P9915
    Daratumumab 99.00%
    Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2].
  • HY-123999
    CD38 inhibitor 1
    CD38 inhibitor 1 (compound 78c) is a potent CD38 inhibitor with IC50s of 7.3 nM and 1.9 nM for hCD38 and mouse CD38[1].
  • HY-N0640
    Kuromanin chloride Inhibitor
    Kuromanin chloride (Chrysontemin) is derived from mulberry leaves and has the effect of increasing blood sugar concentration and maintaining lipid metabolism balance to reduce obesity. Kuromanin chloride can inhibit CD38 enzymatic activities[1][2][3].
  • HY-150508
    MK-0159 Inhibitor 99.72%
    MK-0159 is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart[1].
  • HY-P10563
    Noraramtide
    Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity[1].
  • HY-119648A
    (E/Z)-CCR-11 Inhibitor 98.00%
    (E/Z)-CCR-11 (Comp 12) is a selective CD38 inhibitor, with an IC50 of 20.8 μM against CD38 cyclase. (E/Z)-CCR-11 promotes increases in cellular NAD+ levels and interferon γ[1].
  • HY-P9976A
    Isatuximab (anti-CD38) 98.44%
    Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC)[1].
  • HY-129997
    Luteolinidin chloride 99.14%
    Luteolinidin is a natural deoxyanthocyanidin, isolated from Sorghum bicolor [1]. Luteolinidin is a potent CD38 inhibitor which can protect the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo[2].
  • HY-P9915A
    Daratumumab (PBS)
    Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2].
  • HY-134358A
    Ara-F-NAD+ sodium Inhibitor
    Ara-F-NAD+ sodium is an arabino analogue of NAD+. Ara-F-NAD+ sodium is a potent, reversible and slow-binding CD38 NADase inhibitor[1][2].
  • HY-144987
    RBN013209 98.87%
    RBN013209 is a potent CD38 inhibitor with an IC50 of 0.01-0.1 μM for human CD38. RBN013209 can be used for the research of of cancer[1].
  • HY-134358
    Ara-F-NAD+ Inhibitor
    Ara-F-NAD+ is an arabino analogue of NAD+. Ara-F-NAD+ is a potent, reversible and slow-binding CD38 NADase inhibitor[1][2].
  • HY-156120
    CD38 inhibitor 3 Inhibitor
    CD38 inhibitor 3 (compound 1) is a potent CD38 inhibitor (IC50=11 nM). CD38 inhibitor 3 can promote mitochondrial biogenesis, reduce lactate levels, and increase NAD+ content and Nrf2 expression. In a model of mitochondrial myopathy, CD38 inhibitor 3 increases muscle contraction/development and improves exercise tolerance in Pus1-/- mice[1].
  • HY-P99616
    Felzartamab Inhibitor 99.34%
    Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research[1][2].
  • HY-P990037
    Erzotabart Inhibitor
    Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity[1].
  • HY-P99744
    Modakafusp alfa Inhibitor
    Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules. Modakafusp alfa can be used in the research of multiple myeloma[1].
  • HY-144988
    CD38 inhibitor 2 98.81%
    CD38 inhibitor 2 is a potent CD38 inhibitor (IC50 = 0.01 ~ 0.1 μΜ).